首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1736717

全球輸血診斷市場：市場規模（按組件、應用、最終用戶和地區分類）、未來預測

Global Blood Transfusion Diagnostics Market Size By Component (Reagents & Kits, Instruments), By Application (Blood Grouping, Disease Screening), By End-User (Blood Banks, Hospitals), By Geographic Scope and Forecast

出版日期: 2025年05月06日 | 出版商:

Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄

輸血診斷市場規模及預測

2024 年輸血診斷市場規模價值 56.4 億美元，預計到 2032 年將達到 103.3 億美元，2026 年至 2032 年的複合年成長率為 7.86%。

輸血診斷包括幾個重要的檢測和程序，旨在確保輸血的安全性和相容性。這些檢測有助於確定供血者和受血者的血型是否匹配，從而降低致命輸血反應的風險。重要的檢測包括血型鑑定（用於識別ABO血型和Rh血型）以及交叉配血（用於確認供血者和受血者的血型是否相容）。

這些檢測對於確保輸血的安全性和有效性至關重要，尤其是血型鑑定、交叉配血和傳染病檢查。血型鑑定對於識別供血者和受血者的血型（ABO和Rh）以及預防輸血相關併發症至關重要。交叉配血檢測可以提高供血者和受血者的血液相容性，並降低出現問題的幾率。

隨著檢測速度、準確性和安全性的技術進步，輸血診斷的未來應用預計將持續發展。核酸檢測 (NAT) 等分子診斷方法正日益普及，因為它們能夠以較低劑量更早檢測出病原體，從而提高輸血安全性。

全球輸血診斷市場動態

影響全球輸血診斷市場的關鍵市場動態是：

關鍵市場促進因素

輸血需求不斷成長：主要促進因素之一是，隨著慢性疾病、創傷、手術和急診護理的日益普遍，輸血需求也日益成長。癌症、心血管疾病和貧血等疾病通常需要反覆輸血，這增加了對綜合診斷技術的需求，以確保血液的安全性和相容性。

技術進步：診斷技術的創新正在推動市場擴張。自動化技術、核酸檢測 (NAT) 和次世代定序的使用提高了血液檢測的準確性、速度和可靠性。這些發展減少了人為錯誤，提高了血液傳染疾病的檢測率，並改善了血液相容性檢測的結果，從而增加了對先進診斷設備的需求。

嚴格的安全法規：政府和衛生機構制定了嚴格的安全要求，以減少輸血相關後果，例如溶血反應和感染疾病傳播。這些要求要求對捐血血液進行徹底篩檢，並要求使用最新的診斷設備，包括試劑、設備和軟體，以確保合規。

主要挑戰

嚴格的監管要求：輸血診斷產品受到美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA) 和其他國際監管機構等衛生部門的嚴格監管。這些法規要求進行廣泛的臨床試驗和安全檢驗，這可能會延遲產品核准和上市。

診斷設備成本：先進的診斷設備，尤其是配備分子診斷和核酸檢測等最尖端科技的設備，價格可能高得令人望而卻步。這些成本可能令人望而卻步，尤其對於中低收入國家的小型醫療機構而言。這些技術及其頻繁使用所需試劑的價格限制了其廣泛應用，並阻礙了資源匱乏地區的醫療服務。

供不應求：輸血診斷的有效性取決於能否獲得安全且相容的血液供應。然而，由於捐贈者短缺以及血液採集和儲存方面的後勤挑戰而導致的血液短缺可能會危及診斷過程。

主要趨勢

技術進步：自動化分析儀和分子診斷等先進技術的引入正在改變輸血診斷。自動化解決方案提高了血型鑑定和病原體檢測的速度和準確性，減少了人為錯誤，並提高了實驗室工作流程的效率。

血液成分需求不斷成長：隨著慢性疾病、外科手術和創傷的日益普遍，全球的輸血需求也日益成長。這一趨勢凸顯了對有效輸血診斷技術的需求，以確保血液製品的安全性和相容性。為了因應日益成長的輸血需求，醫療專業人員擴大採用全面的檢測標準。

法規合規性和安全標準：監管機構正在實施更嚴格的規定，以確保輸血程序的安全性和有效性。這些要求需要全面的診斷檢測，從而增加了對高品質試劑、套件和設備的需求。隨著合規性要求日益嚴格，醫療機構正在投資可靠的診斷解決方案，以達到這些安全標準。

Blood transfusion diagnostics include several key tests and procedures designed to assure the safety and compatibility of blood transfusions. These tests assist in determining the optimal match between donor and recipient blood types reducing the danger of potentially fatal transfusion reactions. The key tests are blood typing which identifies ABO and Rh blood groups and cross-matching which confirms compatibility between the donor's and recipient's blood.

These diagnostics are critical for guaranteeing the safety and efficacy of blood transfusions, particularly blood typing, cross-matching, and infectious disease testing. Blood typing is essential for identifying the donor and recipient's blood groups (ABO and Rh) and preventing transfusion-related complications. Cross-matching tests ensure greater compatibility between donor and recipient blood lowering the likelihood of problems.

The future usage of blood transfusion diagnostics is projected to evolve in tandem with technological advancements, improving testing speed, accuracy, and safety. Molecular diagnostics, such as nucleic acid testing (NAT), are gaining popularity allowing for earlier detection of pathogens at lower doses, hence enhancing transfusion safety.

Global Blood Transfusion Diagnostics Market Dynamics

The key market dynamics that are shaping the global blood transfusion diagnostics market include:

Key Market Drivers:

Rising Blood Transfusion Demand: One of the key factors is the increased need for blood transfusions as chronic diseases, trauma cases, surgeries, and emergency treatment become more common. Conditions such as cancer, cardiovascular disease, and anemia frequently necessitate repeated transfusions increasing the necessity for comprehensive diagnostic technologies to ensure blood safety and compatibility.

Technological Advancements: Innovations in diagnostic technology are driving market expansion. The use of automated technologies, nucleic acid testing (NAT), and next-generation sequencing has improved the accuracy, speed, and reliability of blood tests. These developments reduce human error, improve the detection of blood-borne diseases, and provide improved results in blood compatibility testing resulting in increased demand for advanced diagnostic instruments.

Stringent Safety Regulations: Governments and health organizations impose stringent safety requirements to reduce transfusion-related consequences such as hemolytic responses and the spread of infectious infections. These requirements require complete screening of donated blood necessitating the use of modern diagnostics such as reagents, devices, and software, to ensure compliance.

Key Challenges:

Stringent Regulatory Requirements: Blood transfusion diagnostics are subject to stringent regulatory requirements from health authorities such as the FDA, EMA, and other international regulatory bodies. These rules necessitate significant clinical investigations and safety validations which might delay product approval and market introduction.

Diagnostic Tool Costs: Advanced diagnostic equipment, particularly devices equipped with cutting-edge technology such as molecular diagnostics and nucleic acid testing can be prohibitively expensive. These expenses can be prohibitive for smaller healthcare facilities, especially in low- and middle-income nations. The price of these technologies and the reagents necessary for frequent use limits their widespread acceptance presenting barriers to access in resource-constrained places.

Blood Supply Shortages: The efficacy of blood transfusion diagnostics is contingent on the availability of safe and compatible blood supplies. However, blood shortages caused by insufficient donors or logistical challenges during collection and storage can risk the diagnostic process.

Key Trends:

Technological Advancements: The incorporation of sophisticated technology such as automated analyzers and molecular diagnostics is altering blood transfusion diagnosis. Automated solutions increase the speed and accuracy of blood typing and pathogen detection, lowering human error and increasing lab workflow efficiency.

Growing Demand for Blood Components: As chronic diseases, surgical operations, and trauma cases become more common, so does the demand for blood transfusions around the world. This trend emphasizes the need for effective blood transfusion diagnostics to assure safe and compatible blood products. Healthcare professionals are increasingly focused on comprehensive testing standards to manage the growing patient population that requires blood transfusions.

Regulatory Compliance and Safety Standards: Regulatory bodies are enforcing stronger rules to assure the safety and efficacy of blood transfusion procedures. These requirements require comprehensive diagnostic testing which increases the demand for high-quality reagents, kits, and instruments. As compliance requirements become increasingly stringent, healthcare facilities invest in dependable diagnostic solutions to achieve these safety standards.

Global Blood Transfusion Diagnostics Market Regional Analysis

Here is a more detailed regional analysis of the global blood transfusion diagnostics market:

North America:

The North American leads the blood transfusion diagnostics market due to its advanced healthcare infrastructure and high healthcare spending. Canada and Mexico both contribute significantly to market growth to a lesser level. The American Cancer Society estimates that 1.9 million new cancer cases will be identified in the United States in 2021 with many requiring blood transfusions during treatment.

According to the American Red Cross, the United States requires roughly 29,000 units of red blood cells every day. Another important driver is the increasing number of surgical procedures. The aging population also helps to drive market growth as older people are more likely to require blood transfusions. According to the United States Census Bureau, by 2030, all baby boomers will be over the age of 65, bringing the total elder population to 73 million people.

Blood transfusion diagnostics have improved in terms of safety and efficiency thanks to technological breakthroughs such as nucleic acid amplification testing (NAT). The FDA states that NAT can detect HIV 10 to 14 days sooner than previous antibody tests, considerably lowering the risk of transfusion-transmitted infections.

Asia Pacific:

The Asia Pacific blood transfusion diagnostics market is expanding rapidly with the area emerging as the fastest-growing market internationally. This acceleration is mostly due to the increasing population, rising prevalence of chronic diseases, and improved healthcare infrastructure in nations such as China and India. According to the World Health Organization, the prevalence of diabetes in the Western Pacific region, which includes many Asian countries, is anticipated to rise by 57%, from 131 million in 2021 to 206 million in 2045.

This growth in chronic diseases frequently needs blood transfusions, increasing the demand for diagnostic technologies. Furthermore, the growing number of surgical procedures in the region supports market expansion. According to World Bank data, current health expenditure per capita in East Asia and the Pacific has increased by 75%, from $571 in 2010 to $1,001 in 2019. This increased funding has resulted in better-equipped hospitals and blood banks accelerating the implementation of modern blood transfusion testing technology.

Furthermore, government attempts to improve blood safety are driving market expansion. For example, the National AIDS Control Organization (NACO) in India reported that HIV screening of given blood units has increased from 80% in 2007 to 100% in subsequent years, demonstrating the growing importance of blood safety procedures.

Global Blood Transfusion Diagnostics Market: Segmentation Analysis

The Global Blood Transfusion Diagnostics Market is segmented based on Component, Application, End-User, and Geography.

Blood Transfusion Diagnostics Market, By Component

Reagents & Kits
Instruments
Software & Services

Based on the Component, the Global Blood Transfusion Diagnostics Market is bifurcated into Reagents & Kits, Instruments, and Software & Services. Reagents & Kits dominate the global blood transfusion diagnostics market due to their essential role in conducting blood typing, disease screening, and cross-matching tests. These consumables are in constant demand as they are critical for every transfusion procedure regardless of the equipment used. Reagents & kits are used across various healthcare settings including hospitals, blood banks, and diagnostic laboratories ensuring consistent market demand. Additionally, the frequent use and shorter shelf life of reagents and kits drive repeat purchases further boosting their market dominance.

Blood Transfusion Diagnostics Market, By Application

Blood Grouping
Disease Screening

Based on the Application, the Global Blood Transfusion Diagnostics Market is bifurcated into Blood Grouping and Disease Screening. In the global blood transfusion diagnostics market, disease screening is the dominant application. This is primarily driven by the critical need to ensure the safety of blood transfusions by screening for infectious diseases such as HIV, hepatitis, syphilis, and others. With stringent safety regulations in place, disease screening has become a priority to prevent the transmission of infections through blood transfusions. Additionally, advancements in testing technologies such as nucleic acid testing (NAT) have enhanced the ability to detect pathogens with greater accuracy and speed.

Blood Transfusion Diagnostics Market, By End-User

Blood Banks
Hospitals
Diagnostic Laboratories

Based on the End-User, the Global Blood Transfusion Diagnostics Market is bifurcated into Blood Banks, Hospitals, and Diagnostic Laboratories. Hospitals are the dominant end-user in the blood transfusion diagnostics market due to their critical role in administering blood transfusions. Hospitals handle a wide range of medical conditions including surgeries, trauma care, and chronic diseases where blood transfusions are frequently required. As a result, they maintain a constant demand for accurate and timely blood transfusion diagnostics to ensure patient safety and effective treatment outcomes. Additionally, hospitals have integrated diagnostic facilities and blood banks that allow for seamless testing, cross-matching, and transfusion services.

Blood Transfusion Diagnostics Market, By Geography

North America
Europe
Asia Pacific
Rest of the World

Based on Geography, the Global Blood Transfusion Diagnostics Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is the dominant region in the global blood transfusion diagnostics market primarily due to the well-established healthcare infrastructure and the high demand for advanced diagnostic technologies. The region's strong presence of major diagnostic companies such as Abbott Laboratories and Ortho Clinical Diagnostics, drives innovation and adoption of cutting-edge blood testing methods. Additionally, North America has a robust blood donation system and stringent regulations ensuring the safety of transfusions which boosts demand for accurate diagnostic tools. The increasing prevalence of chronic diseases, surgical procedures, and trauma cases further elevates the need for reliable blood transfusion diagnostics.

Key Players

The "Global Blood Transfusion Diagnostics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott Laboratories, Grifols, Bio-Rad Laboratories, Immucor, Ortho Clinical Diagnostics, Quotient Limited, Roche Diagnostics, Haemonetics, Terumo BCT, and Beckman Coulter.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Blood Transfusion Diagnostics Market Key Developments

In November 2023, Grifols announced the Grifols sCD38 solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients.
In March 2022, Mylab Discovery Solutions Pvt. Ltd. launched the NATSpert ID tripleH detection kit, san RT-PCR test that detects infection in given blood.

1 INTRODUCTION OF THE GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY COMPONENT

5.1 Overview
5.2 Reagents & Kits
5.3 Instruments
5.4 Software & Services

6 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY APPLICATIONS

6.1 Overview
6.2 Blood Grouping
6.3 Disease Screening

7 BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY END-USER

7.1 Blood Banks
7.2 Hospitals
7.3 Diagnostic Laboratories

8 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Ortho clinical Diagnostics
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 DiaSorin S.p. A
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Abbott
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Grifols
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 S.A., F.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Hoffmann-La Roche Ltd
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Bio-Rad Laboratories
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Siemens Healthcare Private Limited
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.10 Thermo Fisher Scientific Inc.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.10 Beckman Coulter, Inc
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments